A clinical trial involving insulin lispro was updated to completed status as of September 8, 2026. The study, registered as NCT06948760, is titled "Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D." The trial phase is listed as not applicable.
According to the registry entry, the study focused on adolescents with type 1 diabetes using an automated insulin delivery system. The trial examined a conversion factor related to a more rapidly acting insulin formulation within that delivery system. The event data confirms the study's status as completed but does not include reported outcomes or results at this time.
This update reflects only the change in trial status as recorded in the registry. No efficacy or safety conclusions are provided in the available data. Readers interested in the broader context of insulin lispro, including its approved uses and regulatory status, can consult the compound overview for additional background.